Metabolism and disposition of buspirone
- PMID: 3515929
- DOI: 10.1016/0002-9343(86)90331-1
Metabolism and disposition of buspirone
Abstract
The metabolism and disposition of buspirone have been studied in the rat, the monkey, and in more than 150 human subjects. Buspirone is well absorbed, but is subject to first-pass metabolism. The mean systemic availability is approximately 4 percent. Buspirone is eliminated primarily by oxidative metabolism, which produces several hydroxylated metabolites, including 5-hydroxy-buspirone and 1-pyrimidinylpiperazine. The latter metabolite is from 1 to 20 percent as potent as buspirone in a variety of pharmacologic tests; 5-hydroxybuspirone is essentially inactive. In humans, the systemic exposure to buspirone increases linearly in relation to the oral dose. Food increases the bioavailability of buspirone by decreasing first-pass metabolism; absorption is not markedly altered. The pharmacokinetics of buspirone were not significantly different in men and women or in individuals 21 to 40 years old compared with those over 65 years of age. Half-life values observed in healthy volunteers ranged from two to 33 hours. Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours. The half-life in women tended to be slightly longer than in men, but the difference was not significant. Hepatic cirrhosis resulted in a marked decrease in the clearance of buspirone, which correlated with serum alkaline phosphatase activity. Renal disease produced a modest decrease in buspirone clearance, which could not be correlated with an objective clinical measurement reflecting the severity of renal impairment. Buspirone was not removed by hemodialysis. Buspirone is highly protein bound (more than 95 percent), interacting with both albumin and alpha-acid glycoprotein. However, buspirone did not displace dilantin, propranolol, digoxin, or warfarin from plasma proteins. In rats, buspirone neither inhibited nor induced hepatic mixed-function oxidases. Co-administration of buspirone with amitriptyline or diazepam did not alter the disposition of these agents or their demethylated metabolites.
Similar articles
-
Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.Eur J Clin Pharmacol. 1994;46(1):41-7. doi: 10.1007/BF00195914. Eur J Clin Pharmacol. 1994. PMID: 7911763 Clinical Trial.
-
Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.Clin Pharmacokinet. 1999 Apr;36(4):277-87. doi: 10.2165/00003088-199936040-00003. Clin Pharmacokinet. 1999. PMID: 10320950 Review.
-
The relationship between buspirone bioavailability and dose in healthy subjects.Biopharm Drug Dispos. 1985 Apr-Jun;6(2):139-45. doi: 10.1002/bdd.2510060205. Biopharm Drug Dispos. 1985. PMID: 2860931 Clinical Trial.
-
Pharmacokinetics of pantoprazole in man.Int J Clin Pharmacol Ther. 1996 May;34(5):185-94. Int J Clin Pharmacol Ther. 1996. PMID: 8738854 Clinical Trial.
-
Clinical pharmacokinetics of prazosin.Clin Pharmacokinet. 1980 Jul-Aug;5(4):365-76. doi: 10.2165/00003088-198005040-00004. Clin Pharmacokinet. 1980. PMID: 6994981 Review.
Cited by
-
Insights into the binding of buspirone to human serum albumin using multi-spectroscopic and molecular docking techniques.Heliyon. 2024 Apr 9;10(8):e29430. doi: 10.1016/j.heliyon.2024.e29430. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38638949 Free PMC article.
-
Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.Molecules. 2024 Feb 22;29(5):964. doi: 10.3390/molecules29050964. Molecules. 2024. PMID: 38474476 Free PMC article. Review.
-
Preparation, Swelling, and Drug Release Studies of Chitosan-based Hydrogels for Controlled Delivery of Buspirone Hydrochloride.Curr Pharm Biotechnol. 2024;25(14):1867-1874. doi: 10.2174/0113892010267638231206164415. Curr Pharm Biotechnol. 2024. PMID: 38204236
-
Risk Assessment of Psychotropic Drugs on Mitochondrial Function Using In Vitro Assays.Biomedicines. 2023 Dec 11;11(12):3272. doi: 10.3390/biomedicines11123272. Biomedicines. 2023. PMID: 38137493 Free PMC article.
-
Synthesis of Dihydropyridine Spirocycles by Semi-Pinacol-Driven Dearomatization of Pyridines.Org Lett. 2023 Jan 20;25(2):400-404. doi: 10.1021/acs.orglett.2c04095. Epub 2023 Jan 10. Org Lett. 2023. PMID: 36626565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources